Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriage.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This study aims to assess the effect of VD adjuvant therapy on regulatory T cells and pregnancy outcomes in RM patients.

Why It Was Studied

Recurrent miscarriage (RM) is influenced by immune factors, particularly regulatory T cells, which can impact immune function and miscarriage risk.

Who Took Part

According to the abstract, 104 individuals were involved.

The age groups tagged for this paper are adults.

Clinical data from 104 individuals with RM admitted to their hospital between March 2022 and February 2023 were allocated at random to either the VD group (VDG) or the control group (CG), with 52 patients in each group.

Both groups received standard treatment; the CG was treated with aspirin, while the VDG received additional VD therapy.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Outcomes measured included regulatory T cell proportion, metabolic factors, immune inflammatory markers, and pregnancy outcomes.

What Was Measured

PubMed files the paper under topics including Abortion, Habitual, Vitamin D, Pregnancy Outcome and T-Lymphocytes, Regulatory.

Author keywords: adjuvant therapy, recurrent miscarriage and regulatory T cells.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 104 individuals.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (The journal of obstetrics and gynaecology research), a journal based in Australia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.